Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

s in addition to our prior cash reserves provides us with approximately four years of cash, which we believe is sufficient to complete all three OGX-011/TV1011 (custirsen) Phase 3 trials including the Phase 3 trial in non-small cell lung cancer (NSCLC) that we expect to initiate next year."

"In addition, we now have the financial capacity to expand the OGX-427 program into a second randomized Phase 2 clinical trial. This proposed trial will evaluate OGX-427 in combination with standard chemotherapy as first-line treatment for metastatic bladder cancer, and will enroll approximately 180 patients," added Cormack. "Due to begin in 2011, this trial will complement the ongoing randomized Phase 2 clinical trial in prostate cancer, and Phase 1 clinical trial in superficial bladder cancer. Like custirsen, OGX-427 has broad potential for therapeutic benefit across a number of tumor types including bladder cancer, the fifth most common form of cancer. This underserved patient population is in desperate need of new treatment options." The Company reported a loss for the quarter ended September 30, 2010 of $6.9 million. As of September 30, 2010, cash and investment securities totalled $42.1 million. Together with the estimated $46.7 million proceeds from our October financing, and based on current and planned development activities, management believes existing cash and investment securities will provide adequate resources to fund the Company's currently planned operations into late 2014. Additional Recent Business Highlights

  • On November 2, 2010, the Company was notified that it had been awarded two grants totaling $489,000 under the Internal Revenue Service's Therapeutic Discovery Tax Credit Program. This program was created under the Patient Protection and Affordable Care Act of 2010 to provide tax credits or grants representing up to 50 percent of eligible qualified investments in therapeutic discovery projects during tax years 2009 and 2010. OncoGen
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
    2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
    3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
    4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
    5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
    6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
    7. OncoGenex Reports Second Quarter Financial Results
    8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
    9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
    10. OncoGenex Reports First Quarter Financial Results
    11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
    (Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
    (Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
    (Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
    Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
    ... NEWARK, Del., Feb. 19 Lightwave Logic, Inc. (OTC ... technology company focused on the development of electro-optic polymer ... optical computing, announced today the addition of Anthony J. ... for 30 years in medicinal chemistry and brings a ...
    ... - finally accepts legitimate call by shareholders to general ... - will not allow shareholder ... - persists with high risk, high funding, Avexa merger proposal. ... Meeting scheduled for 27 March 2009 MELBOURNE, Australia, Feb. 19 ...
    ... solar cell materials that are as abundant but much ... today could substantially reduce the cost of solar photovoltaics, ... Resources Group and the Department of Chemistry at the ... Laboratory (LBNL). , These materials, some of which ...
    Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Progen Concedes Shareholder Requisitioned Meeting 2Progen Concedes Shareholder Requisitioned Meeting 3Progen Concedes Shareholder Requisitioned Meeting 4Progen Concedes Shareholder Requisitioned Meeting 5Cheaper materials could be key to low-cost solar cells 2Cheaper materials could be key to low-cost solar cells 3
    (Date:7/9/2014)... injuries have identified an immune marker that predicts ... infection. The study, led by clinician-scientists at Nationwide ... the journal Shock , is part of ... clinical implementation of quick-turnaround immune function tests and ... following critical illness or injury in pediatric patients. ...
    (Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
    (Date:7/9/2014)... With over 100 diseases that can attack soybean crops, ... the most wanted list? University of Illinois scientists cite ... research is needed on the fungus that causes charcoal ... damp growing conditions but Macrophomina phaseolina , the ... drought conditions. , "As the climate continues to change ...
    Breaking Biology News(10 mins):Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bee foraging chronically impaired by pesticide exposure: Study 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
    ... Athens, Ga. University of Georgia researchers are working ... white sturgeon, is struggling in northern California,s Sacramento-San Joaquin ... fish populations and pollution. Doug Peterson and Robert ... and Natural Resources, have begun work on the one-year, ...
    ... lakes has a seriously detrimental impact on people and ... to a study published in the current issue of ... the physicochemical properties and toxicology of water from and ... Singare of Bhavan,s College, in Mumbai, and colleagues highlight ...
    ... of the ocean floor to deep within the human gut ... such an overwhelming majority of life on earth that no ... they maintain the living world around us. Microbes may be ... the most important. In a new two volume ...
    Cached Biology News:UGA researchers study threats to white sturgeon 2UGA researchers study threats to white sturgeon 3Heavy metal -- in and around the lakes 2Handbook of Molecular Microbial Ecology: Exploring the World of the Microbes 2
    ...
    ... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
    ...
    Request Info...
    Biology Products: